PMS-AZITHROMYCIN 600 MG — DIN 02261642
AZITHROMYCIN : 600 MG · PHARMASCIENCE INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is PMS-AZITHROMYCIN?
PMS-AZITHROMYCIN 600 MG contains AZITHROMYCIN : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02261642, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is PMS-AZITHROMYCIN used for?
Treatment of mild to moderate infections: Pharyngitis/tonsillitis, AECB, community-acquired pneumonia, skin infections, GU infections (chancroid, urethritis, cervicitis), and MAC prevention in HIV.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Azithromycin cost around the world?
Azithromycin is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 82 | USD███.██ |
| Saudi Arabia | public | 34 | 55 | SAR███.██ |
| Bahrain | retail (max) | 14 | 29 | BHD███.██ |
| South Africa | single exit price | 24 | 28 | ZAR███.██ |
| Romania | max producer price | 18 | 27 | RON███.██ |
| Greece | producer price (ex-factory) | 25 | 25 | EUR███.██ |
| Australia | ex-manufacturer | 9 | 23 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 7 | 13 | CZK███.██ |
| Luxembourg | reimbursement | 13 | 13 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 9 | 11 | EUR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| United Arab Emirates | public | 4 | 6 | AED███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
320 pack listings across 170 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Azithromycin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Azithromycin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
31 holders have a Canadian DIN containing Azithromycin, across 84 DINs, of which 23 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 4 | 3 | SANDOZ AZITHROMYCIN | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-AZITHROMYCIN, AZITHROMYCIN FOR INJECTION, USP | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 2 | AZITHROMYCIN FOR INJECTION, JAMP-AZITHROMYCIN | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 1 | AZITHROMYCIN, PMS-AZITHROMYCIN | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 4 | 1 | IPG-AZITHROMYCIN, MAR-AZITHROMYCIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 1 | AZITHROMYCIN FOR INJECTION, NOVO-AZITHROMYCIN PEDIATRIC, TEVA-AZITHROMYCIN | Sourceable in Canada |
| APOTEX INC | 3 | 1 | APO-AZITHROMYCIN, APO-AZITHROMYCIN Z | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 3 | 1 | RIVA AZITHROMYCIN, RIVA-AZITHROMYCIN | Sourceable in Canada |
| 10445517 CANADA INC / NORTH PHARMACEUTICALS / DAC PHARMACEUTICALS | 2 | 1 | AZITHROMYCIN | Sourceable in Canada |
| ANGITA PHARMA INC. | 2 | 1 | AG-AZITHROMYCIN | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 1 | M-AZITHROMYCIN | Sourceable in Canada |
| NORA PHARMA INC | 2 | 1 | NRA-AZITHROMYCIN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 600 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: Bottles of 30, 100; blister packs of 6. Suspension: Bottles of 300 mg (15 mL), 600 mg (15 mL), and 900 mg (22.5 mL) with graduated syringe. |
| Storage | Tablets and dry powder: Store at 15-30°C. Reconstituted suspension: Store between 5-30°C; discard unused portion after 10 days. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Azithromycin |
|---|---|
| ATC code | J01FA10 |
| AHFS class | 08:12.12.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02261642 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2261642 |
| Brand name | PMS-AZITHROMYCIN |
| Generic / active ingredient | AZITHROMYCIN : 600 MG |
| Market authorization holder | PHARMASCIENCE INC |
| Health Canada schedule | Prescription |
| ATC code | J01FA10 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01FA |
| Current status | DORMANT |
| Status date | 31-Jul-2026 |
| Original market date | 2006-01-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 500mg Day 1, then 250mg Days 2-5 (Respiratory/Skin). Genitourinary: 1g or 2g single dose. MAC prevention: 1200mg weekly. Pediatrics: 30mg/kg total (Otitis/Pneumonia) or 60mg/kg (Pharyngitis).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin; hypersensitivity to azithromycin, erythromycin, any macrolide, ketolide, or formulation ingredient.
Warnings and precautions
Risk of QT prolongation and torsades de pointes (potentially fatal). Avoid in patients with known proarrhythmic conditions. Hepatotoxicity and serious allergic reactions reported.
Is Azithromycin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
23 of 84 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AZITHROMYCIN | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02480700 |
| APO-AZITHROMYCIN Z | 250 MG | TABLET | APOTEX INC | MARKETED | 02415542 |
| AURO-AZITHROMYCIN | 200 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | 02482371 |
| AURO-AZITHROMYCIN | 100 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | 02482363 |
| AZITHROMYCIN | 250 MG | TABLET | 10445517 CANADA INC / NORTH PHARMACEUTICALS / DAC PHARMACEUTICALS | MARKETED | 02545969 |
| AZITHROMYCIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | 02330881 |
| AZITHROMYCIN | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02442434 |
| AZITHROMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02524449 |
| AZITHROMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02523825 |
| AZITHROMYCIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02483890 |
2 · Same class — other molecules in ATC J01FA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Azithromycin | ACT AZITHROMYCIN · AG-AZITHROMYCIN · APO-AZITHROMYCIN · APO-AZITHROMYCIN Z · +29 more | 84 | 23 | Yes |
| Clarithromycin | APO-CLARITHROMYCIN · APO-CLARITHROMYCIN XL · AVA-CLARITHROMYCIN · BIAXIN · +16 more | 45 | 21 | Yes |
| Erythromycin | ALTI-ERYTHROMYCIN TAB 250MG USP · EES 600 TABLETS 600MG · EES-200 · EES-200 CHEWABLE TBS (ERYPED) · +36 more | 47 | 2 | Yes |
| Spiramycin | ROVAMYCINE 250 CAPSULE 750000 UNIT · ROVAMYCINE 500 CAPSULE 1500000 UNIT | 2 | 0 | Not in Canada |
| Telithromycin | KETEK | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01FF | Clindamycin · Lincomycin | 61 | 24 |
| J01FG | Quinopristin And Dalfopristin | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PMS-AZITHROMYCIN called?
The same molecule, Azithromycin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zithromax | Latin | Australia, Bahrain |
| AZI-ONCE | Latin | Bahrain, Saudi Arabia |
| Azithromycin Viatris | Latin | Australia, Czechia |
| SUMAMED | Latin | Czechia |
| MAZIT | Latin | Bahrain |
| APO-Azithromycin | Latin | Australia |
| Azithromycin Sandoz | Latin | Australia |
| Azithromycin-WGR | Latin | Australia |
| SUMAMED FORTE | Latin | Czechia, Romania |
| ZIMAX | Latin | Bahrain |
| ZITHRO | Latin | Australia |
| ZOCIN | Latin | Bahrain |
| Azitromicina Azevedos | Latin | Saudi Arabia |
| AZITROMYCIN SANDOZ | Latin | Czechia |
| AZOMYCIN | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.